JNJ-55308942

· Janssen Pharmaceutica N.V.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for JNJ-55308942, covering 2025-04-27 to 2025-07-11. Get the full timeline:

Most recent: Clinical Trial Update: A Study of JNJ-55308942 in the Treatment of Bipolar Depression [Phase 2]